Biosensors International, a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care, has launched Chroma, its innovative cobalt chromium bare-metal stent (BMS). The novel platform combines straight and s-shaped link connectors, providing enhanced longitudinal strength while maintaining flexibility. This unique design, combined with the cobalt chromium alloy, results in a robust BMS with thin struts, offering exceptional deliverability while retaining excellent radial strength and extremely low recoil. Chroma's large cell opening also provides ease of access to side branches when necessary.

Chroma is deployed using an advanced delivery system, featuring the smallest tip entry profile in the Biosensors stent range.

"Having consistently led the industry in the development of innovative drug-eluting stents and, more recently, drug-coated stents, we are now set to reinvigorate the bare-metal stent market with the launch of Chroma", commented Jeffrey B Jump, president of Biosensors' Cardiovascular Division. "This will further broaden the range of treatment options that we offer to interventional cardiologists."

Chroma received CE Mark approval in October 2013 and is now in the process of being launched in most major European markets and selected regions in the Middle East, Africa and Asia.